...
机译:在FCR FCR治疗慢性淋巴细胞白血病的持续低淋巴细胞计数与更长的整体存活相关
Sackler Faculty of MedicineTel‐Aviv University Tel‐AvivTel Aviv Israel;
Department of HematologyHadassah Medical CenterJerusalem Israel;
Sackler Faculty of MedicineTel‐Aviv University Tel‐AvivTel Aviv Israel;
Department of HematologyRambam Medical CenterHaifa Israel;
Department of HematologyShaare Zedek Medical CenterJerusalem Israel;
Sackler Faculty of MedicineTel‐Aviv University Tel‐AvivTel Aviv Israel;
Department of HematologyKaplan Medical CenterRehovot Israel;
Soroka Medical CenterBeer Sheba and Ben‐Gurion UniversityBeer Sheva Israel;
Department of HematologyEmek Medical CenterAfula Israel;
Hematology UnitBnai‐Zion Medical CenterHaifa Israel;
Department of HematologyWestern Galilee HospitalNahariya Israel;
Department of HematologyHadassah Medical CenterJerusalem Israel;
Faculty of MedicineHebrew UniversityJerusalem Israel;
Sackler Faculty of MedicineTel‐Aviv University Tel‐AvivTel Aviv Israel;
CLL; FCR; lymphopenia; MRD; prognosis; T reg;
机译:在FCR FCR治疗慢性淋巴细胞白血病的持续低淋巴细胞计数与更长的整体存活相关
机译:风险调整治疗慢性淋巴细胞白血病:II期癌症试验爱尔兰(IE [ICORG 07-01])研究氟氮胺,环磷酰胺和利妥昔单抗治疗评估评估响应适应,缩写前线治疗FCR(17P) CLL.
机译:基于伊布勒替尼(PCI-32765)的随机期III研究与疗法对齐。 标准氟拉西滨,环磷酰胺和Rituximab(FCR)化疗疗效在未处理的慢性淋巴细胞白血病(CLL)中的患者(CLL):ECOG-acrm癌症研究组的试验(E1912)
机译:使用机器学习生存率和分类方法预测慢性淋巴细胞白血病首次治疗的时间
机译:激酶靶向疗法在慢性淋巴细胞性白血病中:获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
机译:复发性慢性淋巴细胞白血病(CLL)患者的FCR和贝伐单抗(FCR-B)治疗
机译:在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中,氟纳比滨,环磷酰胺和Rituximab(FCR)治疗后患者培养有关的骨髓肿瘤